BRAF V600E突变非小细胞肺癌患者全程管理的研究进展

Research progress on whole-course management of non-small cell lungcancer patients with BRAF V600E mutation

肺癌是全球发病及死亡人数最多的恶性肿瘤,其中以非小细胞肺癌(NSCLC)占比最多。鼠类肉瘤病毒癌基因同源物B1(BRAF)是一种原癌基因,与NSCLC的不良预后有关,其中以BRAF V600E突变为代表。近年来,关于BRAF V600E突变NSCLC患者的诊治已成为肺癌精准诊疗研究的焦点,特别是其全程管理备受关注。关于BRAF V600E突变患者的靶向、免疫及化疗等的相关研究层出不穷,该文就国内外相关的研究进展进行综述。

Lung cancer is the malignant tumor with the highest incidence and death in the world,among which non-small cell lung cancer(NSCLC)accounts for the largest proportion.The BRAF gene is a proto-oncogene associated with poor prognosis in NSCLC,represented by BRAF V600E mutations.In recent years,the diagnosis and treatment of NSCLC patients with BRAF V600E mutation has become the focus of accurate diagnosis and treatment of lung cancer,especially its whole-course management.There are many related studies on targeting,immunotherapy and chemotherapy for patients with BRAF V600E mutation.This paper reviewed the relevant research progress at home and abroad.